Brief: Clarity's Theranostic Prostate Cancer Trial Advances To Cohort 2
24/05/2023 14:06
May 24 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX :
* CLARITY'S THERANOSTIC PROSTATE CANCER TRIAL ADVANCES TO
COHORT 2
Source text for Eikon: ID:nPn9RGBya
Further company coverage: CU6.AX
((reuters.briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial